ET
BCRX icon

Entropy Technologies’s BioCryst Pharmaceuticals BCRX Stock Holding History

Entropy Technologies’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$723K Buy
75,908
+19,391
+34% +$151K 0.03% 498
2025
Q4 		$441K Sell
56,517
-11,000
-16% -$79.5K 0.02% 592
2025
Q3 		$512K Buy
67,517
+46,983
+229% +$391K 0.04% 510
2025
Q2 		$184K Buy
+20,534
New +$191K 0.01% 716

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Entropy Technologies's BCRX Position: Q1 2026 in Review

Entropy Technologies increased its BioCryst Pharmaceuticals (BCRX) stake by 34% in Q1 2026, buying an estimated $151K and bringing the position to 75,908 shares worth $723K. The position accounts for 0.03% of the portfolio, ranked #498.

Entropy Technologies first reported a position in BCRX in Q2 2025 and has held it in 4 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Entropy Technologies held 75,908 shares of BioCryst Pharmaceuticals worth $723K as of Q1 2026.
  • Entropy Technologies bought 19,391 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $151K.
  • BioCryst Pharmaceuticals made up 0.03% of Entropy Technologies's portfolio in Q1 2026, its #498 holding.
  • Entropy Technologies first reported a position in BioCryst Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Entropy Technologies's 13F filing for Q1 2026, filed 14 May 2026.